@Bgall and @49parkn, I am not disputing this is a great company. I concur with those sentiments.
The company is on track to make ~$10m EBIT (from $100m gross revenue) this year but has been trading at a valuation of over $500m. A 50x multiple is a little bit excessive for a business of this nature.
It seems more likely that a 10-15x EBITDA multiple would be more appropriate which is consistent with high growth healthcare/ medtech enterprises.
I think it would be naive of us to not expect Ben and Matua to sell down 30% or more of their stock to realise some gains.
IMHO GLTA DYOR
- Forums
- ASX - By Stock
- VIT
- Bell Potter Ratings
Bell Potter Ratings, page-12
-
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VIT (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.1¢ |
Change
-0.009(9.00%) |
Mkt cap ! $54.13M |
Open | High | Low | Value | Volume |
9.9¢ | 9.9¢ | 9.1¢ | $11.00K | 116.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 49400 | 9.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.7¢ | 1 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 49400 | 0.091 |
2 | 16077 | 0.090 |
2 | 132179 | 0.089 |
2 | 44615 | 0.088 |
2 | 67377 | 0.087 |
Price($) | Vol. | No. |
---|---|---|
0.087 | 1 | 1 |
0.099 | 11307 | 1 |
0.100 | 135200 | 2 |
0.105 | 66346 | 3 |
0.110 | 33613 | 2 |
Last trade - 15.59pm 17/07/2024 (20 minute delay) ? |
Featured News
VIT (ASX) Chart |